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6A 9-year-old female sought attention for acute
dental pain in the right lateral mandible. Physical
examination revealed swelling and loss of the
normal mandibular angle on the right side. Radio-
graphs revealed an expansile lesion in the right
mandible and subsequent biopsy was consistent
with a diagnosis of giant cell tumor (GCT). After
two surgical removals and four corticosteroid
injections,1 radiographs 21 months later revealed741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights rese
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E-mail address: lietmas@ccf.org (S.A. Lietman).progressive enlargement of the lesion. She was
subsequently referred to the Johns Hopkins Hospi-
tal (Fig. 1a) where, based on the diagnosis of
GCT, she was treated with interferon alpha 2 (ro-
feron-A).2 However, after 4 months of treatment
there was no clinical improvement prompting a
review of the original diagnosis. Serum levels of
VEGF, a marker for GCT, were not elevated.3–6
and immunostaining of the original tumor for fac-
tor VIII, a marker of the neovascularization that is
typical of GCT, was also negative. Moreover
histological analysis did not disclose increased tu-
mor vascularity, and the overall impression was
consistent with giant cell granuloma (GCG).rved.
Figure 1 (a) At the time of presentation at the authors institution, after surgical and corticosteroid treatment but
before calcitonin treatment. (b) After one year of calcitonin treatment.
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treatment was begun with daily injection of sal-
mon calcitonin 100 units SQ.4,7,8 After one year
of treatment with calcitonin the lesion had re-
solved completely by physical examination as well
as radiological evaluation (Fig. 1b). Three years
after discontinuation of therapy she has no evi-
dence of recurrence.Discussion
Giant cell-containing lesions of the jaw include
GCT, GCG, Cherubism, and fibrous dysplasia
of the jaw and can be difficult to distinguish
histologically.1,9
GCT has been associated with vascular prolifera-
tion and increased secretion of VEGF. These factors
have led to the suggestion that interferon is a use-
ful treatment.2 In the case reported here, Immuno-
staining for expression of factor VIII, an endothelial
cell produced protein that serves as a marker of
vascularity, was negative, and a diagnosis of GCG
became more probable.
Genetic approaches now permit definitive iden-
tification of at least some of these lesions. Germ-
line mutations in the SH3BP2 gene have been
described in Cherubism and somatic cell mutations
in GNAS are present in fibrous dysplasia.
Calcitonin has been used previously to treat a
small number of patients with GCG with good suc-cess.10 We report here on a patient with GCG that
was refractory to surgery and interferon but re-
sponded dramatically to calcitonin.References
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